Peer-reviewed veterinary case report
15-week CHOP chemo for dogs with multicentric lymphoma results
By Curran, K & Thamm, D H·Published in Veterinary and comparative oncology·2016·Colorado State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric lymphoma, a type of cancer affecting the lymph nodes, were treated with a shorter 15-week chemotherapy plan using a combination of drugs known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). Remarkably, 98% of the dogs responded well to the treatment, with 104 achieving complete remission. On average, dogs lived for about 311 days after starting treatment, and many experienced a good quality of life during that time. This shorter protocol may be a good option for pet owners who are concerned about the length and intensity of traditional chemotherapy treatments.
People also search for: dog lymphoma treatment options · CHOP chemotherapy for dogs · canine cancer survival rates
Abstract
Standard of care treatment of dogs with multicentric lymphoma includes combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); however, owners may be hesitant to commit the resources necessary to complete a lengthy, multi-drug protocol. One hundred thirty-four client-owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol. The overall response rate was 98% with 104 dogs experiencing a complete response (CR). The median progression-free survival (PFS) time for all dogs was 176 days, and the median disease-specific overall survival time was 311 days. Prognostic factors identified on multivariate analysis as significant for PFS included substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing a CR as best response to therapy. In conclusion, this protocol may be a viable alternative to CHOP protocols using a larger number of treatments.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26279153/